• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尤因肉瘤家族性肿瘤对芬维A胺诱导的细胞死亡的敏感性通过EWS-Fli1依赖的p38(丝裂原活化蛋白激酶)活性调节而增加。

The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38(MAPK) activity.

作者信息

Myatt S S, Burchill S A

机构信息

Candlelighter's Children's Cancer Research Laboratory, Cancer Research UK Clinical Centre, St James's University Hospital, Leeds, UK.

出版信息

Oncogene. 2008 Feb 7;27(7):985-96. doi: 10.1038/sj.onc.1210705. Epub 2007 Aug 13.

DOI:10.1038/sj.onc.1210705
PMID:17700534
Abstract

The Ewing's sarcoma family of tumours (ESFT) are small round cell tumours characterized by the non-random EWS-ETS gene rearrangements. We have previously demonstrated that ESFT are highly sensitive to fenretinide-induced death, effected in part through a reactive oxygen species (ROS)-dependent pathway. Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG. This decrease in cell death was independent of the level of ROS produced following exposure to fenretinide, but was effected through EWS-Fli1-dependent modulation of p38(MAPK) activity. Furthermore, inhibition of p38(MAPK) activity and knockdown of EWS-Fli1 reduced fenretinide-induced mitochondrial permeabilization, cytochrome c release, caspase and PARP cleavage, consistent with the hypothesis that p38(MAPK) is critical for activation of the death cascade by fenretinide in ESFT cells. These data demonstrate that expression of EWS-Fli1 enhances fenretinide-induced cell death in ESFT and that this is effected at least in part through modulation of p38(MAPK) activity.

摘要

尤因肉瘤家族性肿瘤(ESFT)是一类小细胞圆形肿瘤,其特征为非随机的EWS-ETS基因重排。我们之前已经证明,ESFT对芬维A胺诱导的死亡高度敏感,部分是通过活性氧(ROS)依赖的途径实现的。在此,我们首次证明,致癌融合蛋白EWS-Fli1下调后,ESFT细胞对芬维A胺诱导的细胞死亡的敏感性降低;靶向EWS-Fli1的小干扰RNA(siRNA)减弱了在表达EWS-Fli1而非EWS-ERG的细胞系中芬维A胺诱导的细胞死亡。这种细胞死亡的减少与暴露于芬维A胺后产生的ROS水平无关,而是通过EWS-Fli1依赖的p38(丝裂原活化蛋白激酶)活性调节实现的。此外,抑制p38(丝裂原活化蛋白激酶)活性和敲低EWS-Fli1可减少芬维A胺诱导的线粒体通透性转变、细胞色素c释放、半胱天冬酶和聚(ADP-核糖)聚合酶裂解,这与p38(丝裂原活化蛋白激酶)对ESFT细胞中芬维A胺激活死亡级联反应至关重要的假设一致。这些数据表明,EWS-Fli1的表达增强了ESFT中芬维A胺诱导的细胞死亡,并且这至少部分是通过调节p38(丝裂原活化蛋白激酶)活性实现的。

相似文献

1
The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38(MAPK) activity.尤因肉瘤家族性肿瘤对芬维A胺诱导的细胞死亡的敏感性通过EWS-Fli1依赖的p38(丝裂原活化蛋白激酶)活性调节而增加。
Oncogene. 2008 Feb 7;27(7):985-96. doi: 10.1038/sj.onc.1210705. Epub 2007 Aug 13.
2
Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro.通过RNA干扰靶向EWS/FLI-1可在体外减弱尤因肉瘤细胞的肿瘤表型。
J Orthop Res. 2004 Jul;22(4):910-7. doi: 10.1016/j.orthres.2003.12.008.
3
STAT3 is activated in a subset of the Ewing sarcoma family of tumours.信号转导和转录激活因子3(STAT3)在尤因肉瘤家族性肿瘤的一个亚群中被激活。
J Pathol. 2006 Apr;208(5):624-32. doi: 10.1002/path.1941.
4
p38MAPK-Dependent sensitivity of Ewing's sarcoma family of tumors to fenretinide-induced cell death.尤文肉瘤家族性肿瘤对芬维A胺诱导的细胞死亡的p38丝裂原活化蛋白激酶依赖性敏感性。
Clin Cancer Res. 2005 Apr 15;11(8):3136-48. doi: 10.1158/1078-0432.CCR-04-2050.
5
Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators.缺氧可降低维甲酸对尤因肉瘤和原始神经外胚层肿瘤细胞系的细胞毒性,而神经酰胺调节剂可协同增强这种细胞毒性。
Cancer Res. 2004 Aug 1;64(15):5415-24. doi: 10.1158/0008-5472.CAN-04-0377.
6
Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.编码转化生长因子-β II型受体的基因的抑制是EWS-FLI1癌蛋白的主要作用靶点。
Nat Genet. 1999 Oct;23(2):222-7. doi: 10.1038/13854.
7
EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors.EWS-FLI1融合蛋白上调神经嵴发育中的关键基因,并导致尤因家族肿瘤所观察到的表型。
Cancer Res. 2005 Jun 1;65(11):4633-44. doi: 10.1158/0008-5472.CAN-04-2857.
8
Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells.甲羟戊酸和N-糖基化在尤因肉瘤细胞中EWS/FLI-1融合蛋白增殖及表达中的调控作用
Exp Cell Res. 1999 Jan 10;246(1):38-46. doi: 10.1006/excr.1998.4280.
9
EWS-Fli1 up-regulates expression of the Aurora A and Aurora B kinases.EWS-Fli1上调极光激酶A和极光激酶B的表达。
Mol Cancer Res. 2008 Dec;6(12):1937-45. doi: 10.1158/1541-7786.MCR-08-0054.
10
Identification of various exon combinations of the ews/fli1 translocation: an optimized RT-PCR method for paraffin embedded tissue -- a report by the CWS-study group.EWS/Fli1易位各种外显子组合的鉴定:一种针对石蜡包埋组织的优化逆转录聚合酶链反应方法——CWS研究小组的报告
Klin Padiatr. 2004 Nov-Dec;216(6):315-22. doi: 10.1055/s-2004-832338.

引用本文的文献

1
Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells.金诺芬和活性氧抑制尤因肉瘤细胞中的蛋白质合成并调节PLK1蛋白水平。
Front Oncol. 2024 Jun 12;14:1394653. doi: 10.3389/fonc.2024.1394653. eCollection 2024.
2
Genomic nursing science revealed the prolyl 4-hydroxylase subunit alpha 2 as a significant biomarker involved in osteosarcoma.基因组护理科学揭示脯氨酰4-羟化酶亚基α2是参与骨肉瘤的重要生物标志物。
Heliyon. 2024 Feb 29;10(5):e27191. doi: 10.1016/j.heliyon.2024.e27191. eCollection 2024 Mar 15.
3
Targeting Sphingolipids for Cancer Therapy.
靶向鞘脂用于癌症治疗。
Front Oncol. 2021 Oct 19;11:745092. doi: 10.3389/fonc.2021.745092. eCollection 2021.
4
RNA sequencing and functional studies of patient-derived cells reveal that neurexin-1 and regulators of this pathway are associated with poor outcomes in Ewing sarcoma.对患者来源细胞进行 RNA 测序和功能研究表明,神经连接蛋白 1 及其通路的调节因子与尤文肉瘤的不良预后相关。
Cell Oncol (Dordr). 2021 Oct;44(5):1065-1085. doi: 10.1007/s13402-021-00619-8. Epub 2021 Aug 17.
5
Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.尤文氏肉瘤家族肿瘤的最佳治疗管理:系统治疗的最新进展。
Paediatr Drugs. 2013 Dec;15(6):473-92. doi: 10.1007/s40272-013-0037-1.
6
Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma.基于细胞的小分子化合物筛选鉴定芬维 A 酯为潜在的转位阳性横纹肌肉瘤治疗药物。
PLoS One. 2013;8(1):e55072. doi: 10.1371/journal.pone.0055072. Epub 2013 Jan 25.
7
Detection and characterisation of multi-drug resistance protein 1 (MRP-1) in human mitochondria.检测和鉴定人线粒体中的多药耐药蛋白 1(MRP-1)。
Br J Cancer. 2012 Mar 13;106(6):1224-33. doi: 10.1038/bjc.2012.40. Epub 2012 Feb 21.
8
Heterogeneous role of the glutathione antioxidant system in modulating the response of ESFT to fenretinide in normoxia and hypoxia.谷胱甘肽抗氧化系统在调节 ESFT 对芬维 A 酯在常氧和低氧环境中的反应中的异质作用。
PLoS One. 2011;6(12):e28558. doi: 10.1371/journal.pone.0028558. Epub 2011 Dec 8.
9
Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases.人肝微粒体、细胞色素 P450 酶和 UDP-葡糖醛酸基转移酶对芬维 A 胺代谢的特征。
Br J Pharmacol. 2011 Feb;162(4):989-99. doi: 10.1111/j.1476-5381.2010.01104.x.
10
Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer.定义抑制子宫内膜癌中肿瘤抑制基因 FOXO1 表达的 microRNAs。
Cancer Res. 2010 Jan 1;70(1):367-77. doi: 10.1158/0008-5472.CAN-09-1891. Epub 2009 Dec 22.